Jennifer J. Arnold

152 Marsden St
Parramatta, NSW 2150, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 91 publications

Twelve-Month Real-World Outcomes of Faricimab for Treatment-Naive Neovascular AMD in Australia.

Twelve-Month Real-World Outcomes of Faricimab for Treatment-Naive Neovascular AMD in Australia.

Journal: Clinical & experimental ophthalmology

Published: November 04, 2025

Expert consensus on fundus fluorescein angiography reporting in ophthalmology: a Delphi study.

Expert consensus on fundus fluorescein angiography reporting in ophthalmology: a Delphi study.

Journal: The British journal of ophthalmology

Published: October 21, 2025

PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysis.

PRevEnting FracturEs in REnal Disease-1 (PREFERRED-1): protocol for a pilot study of a pragmatic, randomised controlled trial of denosumab for the prevention of fragility fractures in haemodialysis.

Journal: BMJ open

Published: September 11, 2025

Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study group.

Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study group.

Journal: The British journal of ophthalmology

Published: April 29, 2025

Readiness of optometrists in the management of geographic atrophy: a survey of optometrists in Australia.

Readiness of optometrists in the management of geographic atrophy: a survey of optometrists in Australia.

Journal: Clinical & experimental optometry

Published: April 02, 2025

Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry.

Outcomes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry.

Journal: Clinical & experimental ophthalmology

Published: March 03, 2025

Basal Linear Deposit: Normal Physiological Ageing or a Defining Lesion of Age-Related Macular Degeneration?

Basal Linear Deposit: Normal Physiological Ageing or a Defining Lesion of Age-Related Macular Degeneration?

Journal: Journal of clinical medicine

Published: July 03, 2024

Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry.

Twelve-Month Outcomes of Brolucizumab in Routine Clinical Practice: Fight Retinal Blindness! Registry.

Journal: Clinical & experimental ophthalmology

Published: April 12, 2024

Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration.

Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration.

Journal: The British journal of ophthalmology

Published: April 05, 2024

One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.

One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry.

Journal: Ophthalmology. Retina

Published: August 28, 2023

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.

Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the AUSSIEDEX study.

Journal: BMJ open ophthalmology

Published: December 09, 2022

An Ocular Chameleon.

An Ocular Chameleon.

Journal: The Neurohospitalist

Published: September 23, 2022

Showing 1-12 of 91

Last Updated: 09/26/2026